OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Hmmmmm, I keep getting lucky with this share.

I was right yesterday, when I said it may be time to get back in again.

Nice profit since yesterday but I think it is time to sell again.

Fallen back again since I sold.

This seems to be my lucky share.

Of course now that I've said that, it will prove me wrong & shoot up again.

Maybe this time I sold too early but a profit is a profit.

apple be careful with this one mate as it may well just catch you out release RNS and whoosh. Good luck

DSTOREY9916

You are right about RNS and whoosh, this company still looks good to me.

BUT it may fall back again before that happens due to the current volatile markets not due to fundamentals.

I keep making money when there are sudden dips in this share & then sudden recoveries when I sell again.

I picked OXB in the MoneyAM share of the year competition & I still think it might be.

Current market conditions persuade me to keep getting in & out but that will change.

Sells outnumber buys by 3 to 1 so far today, going the opposite way to the market.

Got a funny feeling we are in for a sudden drop.

Have to agree regards RNS, this one will fly and for all the right reasons ie being a provider of anti cancer treatments!!!!
Best of luck to all....DST

apple buys now coming in....

DSTOREY9916

Yep I saw it turn around just after my last post so I joined in.

BUT I'm not quite so confident this time.

Looking as though it is about to test WMA 20, could be intersting as it still has good level of support according to RSI......DST

DStorey

What do WMA 20, RSI & DST mean?

Please help someone not familiar with these names.

raptor,

WMA weighted movement average over 20 day period

RSI relative strength index

DST my initials!!!

look at www.comdirect.co.uk, and sign up for their chart analysis tool all will come clearer there mate.

Regards DST

Still rising :-)

Maybe I've got it right yet again.

I was wrong this morning but that didn't cost me anything.

DStorey

Thankyou.

relative strength index?

Relative to what?

I'll see what a search engine turns up but if you have a moment then feel free to comment.

Down again, like I said the other day I wasn't so confident this time.

Glad I didn't put much in.

When 1 of the drug trials succeeds I'll wish that I'd put more in.

More importantly when not if pipeline comes through we can look at going some way to f@%king cancer.....

Great news out today, share price should now show an upward trend from here - my target 25 by Sept, 32 by next Jan, but who knows?..could see this really shoot soon

Agree strongly very encouraging especially those suffering from Parkinson's.

and motor neuron....

Hope it works

Oxford Bio reaches nerve milestone
By Clive Cookson, Science Editor
Published: June 1 2004 19:20 | Last Updated: June 1 2004 19:20


The prospect of treating spinal injuries through gene therapy will take another step closer to reality on Wednesday when Oxford Biomedica announces that its nerve repair product has restored feeling and movement to animals with damaged limbs.


The Oxford-based company said in December that its scientists had observed regrowth of nerves in rats treated with Innurex.

Nicholas Mazarakis, head of neurobiology, will tell the annual meeting of the American Society of Gene Therapy in Minneapolis on Wednesday that the product has restored function to the injured limbs.

"When I saw the data - how well we were getting back both sensory and motor functions - I was stunned," said Alan Kingsman, chief executive of Oxford Biomedica. "We felt we should repeat the experiments to confirm these exciting results."

The company and its academic partners at King's College London were talking to clinicians about how best to test Innurex in paralysed patients. "I think we could be going clinical in 2006," Prof Kingsman said.

The rats tested were an animal model for "avulsion injury", a common cause of paralysis in sporting and motor accidents, in which nerves are damaged by very rapid stretching or pulling. The Christopher Reeve Foundation - set up by the Hollywood actor paralysed after a riding accident in 1995 - recently gave King's College a grant to explore the use of Innurex in spinal cord injuries similar to the one suffered by Mr Reeve.

Innurex uses a virus to carry a gene called RARbeta2 to injured nerves. This gene - normally active in embryos but not in adults - makes the cells receptive to body chemicals that stimulate the growth of next nerve connections.

Most experiments to repair spinal injuries have not used gene therapy but other techniques including the application of cells or growth factors to the injury. But none has yet given convincingly reproducible results in animal experiments. "Stem cell therapy must be at least 10 years away, even if you take the most optimistic view of the stem cell story," said Prof Kingsman.

Oxford Biomedica has six gene therapy products in pre-clinical development or early clinical trials, either for cancer or to treat damaged nerves or brain cells. Innurex is one of the most promising. The shares closed down p at 16p.

http://news.ft.com/servlet/ContentServer?pagename=FT.com/StoryFT/FullStory&c=StoryFT&cid=1085944439149